Professor Sir Munir Pirmohamed
Professor Sir Munir Pirmohamed MB ChB, PhD, FRCPE, FRCP, FBPhS, FMedSci is David Weatherall Chair in Medicine at the University of Liverpool, and a Consultant Physician at the Royal Liverpool University Hospital. He is Director of the Centre for Drug Safety Sciences, and Director of the Wolfson Centre for Personalised Medicine. He is also Director of HDR North. He is an inaugural NIHR Senior Investigator, Fellow of the Academy of Medical Sciences in the UK, Commissioner on Human Medicines. He was President of British Pharmacological Society from January 2020 - December 2021, and is currently President of the Association of Physicians. He was awarded a Knights Bachelor in the Queen's Birthday Honours 2015. His research focuses on personalised medicine, clinical pharmacology and drug safety.
Vicky Chaplin
.JPG)
Vicky is the Senior Clinical Lead for the Genomics Unit at NHS England, overseeing the multidisciplinary healthcare professional team and their associated workstreams. She also supports the development of clinical informatics within genomics and is the Clinical Safety Officer for the Genomics Unit, chairing the NHS Genomic Medicine Service’s Clinical Safety Group. A pharmacist by profession, she works in collaboration with the NHS GMS Alliances’ Pharmacy Leads and other key stakeholders to embed genomic medicine into mainstream care and enable patients to realise the benefits of medicines optimisation driven by genomic and diagnostic characterisation. This lead role is also part of the Chief Pharmaceutical Officer’s Senior Leadership Team and Pharmacy Advisory Group ensuring the work is coordinated across pharmacy and medicines developments across the NHS and government. She co-led the development of the NHSE Pharmacy Genomics Workforce, Education and Training Strategic Framework with National Genomics Education and continues to direct the implementation of this for the whole pharmacy workforce. During her career, Vicky has worked across various sectors of pharmacy in the NHS, including primary care, secondary care and community pharmacy as well as in regional and national roles supporting medicines optimisation and the use of medical devices, including digital therapeutics. She is a previous Chief Pharmaceutical Officer’s Clinical Fellow and has also worked as a Medical Advisor in the pharmaceutical industry, with a significant part of her role focusing on the intersection of medicines, medical devices and digital tools. Her specialist area of interest is diabetes, and as well as undertaking postgraduate studies in genomic medicine, she holds additional qualifications in clinical pharmacy, as an independent prescriber, and in health economics.
Adrian Llerena
Adrián LLerena is the Director of Extremadura Biosanitary Research Institute and the Clinical Research Center in the University Hospital Ien Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in the Medical Schools of the University of Extremadura Spain and it was part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics. His teaching experience is of more than 30 years in Spain and of about 9 years in Portugal. He has supervised more than 25 PhD thesis so far. He has also been an invited as Professor in different Universities in USA such as University of California at Los Angeles 2004 Mount Sinai Medical School at NY 2005 and Miller Medical School at Miami 2006 and in Latin America such as UNAM in Mexico San Marcos in Peru Chile Brasil etc. He has published more than 200 peer reviewed papers and book chapters. He is also coordinating the RIBEF IberoAmerican network of Pharmacogenetics since 2006. He served in different Scietific societies as IberoAmerican Society of Pharmacogenomics. He has been Principal Investigator in more than 25 national and European research projects. He has also served as reviewer in all journals related to clinical pharmacology and mainly pharmacogenetics and clinical psychopharmacology. Currently is the leader of the IMPaCT WP05-Pharmacogenenetics Clinical Implementation in the Spanish public health System and MedeA in Extremadura. Since 2010 is Scientific Expert-Advisor at EMA Pharmacogenomics -MWP. He has been Vicepresident of the SEFC Spanish Society of Clinical Pharmacology and President the SEFF Spanish Society of Pharmacogenetics and Pharmacogenomics (2019-2023), and Board Member of ESPT European Society of Pharmacogenomics and Pesonalized Therapeutics.
